
Garetosmab
Garetosmab (REGN2477) is a fully human anti-activin A antibody for TGF-beta research. Sold per vial, 0.1 mg to 100 mg.
Single vialFreeze-dried powder4.8 on Trustpilot
Also known as REGN2477
For research and laboratory use only. Not for human consumption.
- Batch
- Delivery
- Free tracked shipping to 150+ countries. Delivery guaranteed. How delivery works
- Report
- 98.4% Purity Verified · SEC-HPLC / SDS-PAGE / Intact Mass / ELISA Tested · Delivery photos
- Guarantee
- If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.
- Help
- A person answers on WhatsApp, even at 3 a.m. your time.
Garetosmab: Key Facts
Garetosmab is a muscle growth research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 5 formats. Each batch is independently HPLC-verified at 98.4% purity by Janoshik Analytical, with the certificate of analysis for the batch we're shipping now published on the lab-results page.
Third-party verified batch
| Compound | Garetosmab |
|---|---|
| Research category | Growth hormone |
| Available formats | 0.1mg x 1 vial, 1mg x 1 vial, 5mg x 1 vial, 10mg x 1 vial, 100mg x 1 vial |
| Strength shown | 0.1 mg |
| Molecular weight | ~145,500 g/mol (145.5 kDa) |
| CAS number | 2097125-54-5 |
| Batch | LZ-GAR-261001 |
| Purity | 98.4% verified (third-party HPLC, Janoshik) |
| Test method | SEC-HPLC / SDS-PAGE / Intact Mass / ELISA |
| Certificate of analysis | Published online for the batch we're shipping now |
| Intended use | Laboratory research use only. Not for human consumption. |
| Handling | Supplied lyophilized, store per the stability guide |
Good to know
The report is online before you order. Check the batch and its test date, then decide.
Your price drops with every kit. Any mix counts, up to 42% off at 50 kits.
What Researchers Say
Read All ReviewsIndependent research lab
United States
"Bought the 5mg for an ACVR1 model. The selectivity counter-screen on the certificate covers the whole BMP list, which is exactly what we needed to rule out cross-talk."
2026-08-07
Lukas B.
Germany
"Twelve days to arrive. The certificate was published online before I ordered."
2026-08-03
Independent testing lab
Australia
"SEC monomer came back at 98.6 on our column against 98.7 stated. Close enough that we trust the rest of the sheet."
2026-07-30
About This Product
Garetosmab (REGN2477) Research Guide
What is Garetosmab?
Garetosmab is a fully human IgG4 monoclonal antibody that binds and neutralises activin A. Its development code is REGN2477. It was generated by Regeneron on the VelocImmune platform, the same fully-human-antibody platform behind Trevogrumab.
Key identifiers: CAS 2097125-54-5, approximately 145.5 kDa, IgG4 isotype. Expressed in Chinese hamster ovary cells and purified by Protein A affinity chromatography.
Garetosmab is not a peptide. It is a four-chain immunoglobulin, two heavy and two light chains, disulfide-linked and N-glycosylated. Peptide synthesis cannot produce it and a peptide certificate cannot characterise it.
How does Garetosmab work?
Activin A is a TGF-beta superfamily ligand, a homodimer of two inhibin beta-A subunits. It signals through the activin type II receptors ActRIIA and ActRIIB paired with ALK4, driving SMAD2 and SMAD3 phosphorylation.
Garetosmab is a ligand trap: it binds activin A and blocks receptor engagement.
What makes it useful is the precision of that binding. Garetosmab binds and inhibits activins containing the inhibin beta-A subunit, meaning activin A, activin AB and activin AC. It does not bind or functionally inhibit:
- activin B
- inhibin A
- BMP-2, BMP-6, BMP-9, BMP-10
- GDF8 (myostatin)
- GDF11
Why is activin A selectivity hard, and why does it matter?
The TGF-beta superfamily is a crowded receptor space. Activin A, activin B, myostatin, GDF11 and several BMPs converge on a small set of shared type I and type II receptors and feed the same SMAD transcriptional machinery. A tool that binds four of them produces a phenotype no downstream assay can decompose.
Garetosmab draws its line at the ligand rather than the receptor. Anything it does in a model can be attributed to activin A, AB or AC and to nothing else on that list. For designs that must separate activin signalling from BMP signalling in the same tissue, that specificity is the whole value of the reagent.
What is the FOP and ACVR1 research context?
Regeneron scientists identified activin A as the driver of heterotopic ossification in fibrodysplasia ossificans progressiva (FOP), an ultra-rare condition in which the mutant ACVR1 receptor misreads activin A as an osteogenic signal. In healthy tissue activin A does not drive bone formation; in FOP the mutant receptor converts it into a bone-forming input.
In the reported Phase 2 study, garetosmab cut new heterotopic ossification lesions by 90% to 94% against placebo (1 to 2 new lesions against 19).
The FDA granted Fast Track designation in 2017 and, after the Phase 3 OPTIMA trial, approved garetosmab on 19 August 2026 as Pasatru, for adults with FOP. Material supplied here is a research reagent, unrelated to any clinical supply chain.
What did COURAGE show about garetosmab, including tolerability?
Garetosmab was the third agent in Regeneron's Phase 2 COURAGE obesity trial (NCT06299098), added on top of semaglutide and Trevogrumab. Results were presented at EASD 2025.
Change in lean body mass from baseline at 26 weeks:
- Semaglutide alone: -6.5%
- Semaglutide + trevogrumab (two strengths): -3.3% and -3.8%
- Semaglutide + trevogrumab + garetosmab: -2.0%
The triplet reached 80.9 percent lean mass preservation and a 27.3 percent increase in fat mass reduction versus semaglutide alone, the strongest body-composition result in the study.
It also carried the worst tolerability. Semaglutide plus trevogrumab was generally well tolerated, but the triplet had a substantially higher rate of discontinuations for tolerability and other adverse events. Adverse events reported in at least 5 percent of any group included muscle spasms, nausea, constipation, fatigue, diarrhoea, headache, vomiting, gastro-oesophageal reflux, upper respiratory tract infection, nasopharyngitis, urinary tract infection, influenza and COVID-19.
That trade-off, the best body composition and the worst discontinuation rate in the same arm, is the single most useful thing to know about this compound, and it is why activin A blockade is studied as an addition rather than a default.
Research applications
- Activin A pathway pharmacology and ligand-selective neutralisation
- SMAD2 and SMAD3 signalling studies requiring separation of activin from BMP inputs
- ACVR1 and heterotopic ossification research models
- Muscle and metabolic research, where activin A is a second ActRII ligand alongside myostatin
- Paired studies with Trevogrumab to dissect activin A and myostatin contributions in one model
- Comparative work against non-selective approaches such as follistatin or soluble ActRIIB-Fc decoys, which bind activin A and myostatin both and cannot separate the two
- Antibody handling, formulation and stability method development
Why run Garetosmab and Trevogrumab together?
Myostatin and activin A are the two principal ActRII ligands restraining skeletal muscle mass, and they signal through overlapping receptors into the same SMAD pathway. Blocking one leaves the other intact, which is why single-ligand results in this space are frequently smaller than receptor-level blockade predicts.
COURAGE is the clearest demonstration: trevogrumab alone took lean mass loss from -6.5% to -3.3%, and adding garetosmab took it to -2.0%. Running both antibodies alone and in combination is the standard design for apportioning an ActRII-blockade phenotype between the two ligands. Since neither antibody cross-reacts with the other's target, the combination is genuinely additive rather than confounded.
For how both compare against the receptor-level and pro-form-selective approaches, see the myostatin inhibitor comparison guide.
How is an antibody tested differently from a peptide?
A peptide certificate reports reversed-phase HPLC purity, an ESI-MS charge state and Karl Fischer water. For a 145 kDa glycoprotein none of those are the right measurement: reversed-phase conditions denature the molecule, a single-charge-state mass is meaningless against a glycan-heterogeneous population, and the impurities that matter are not synthesis by-products.
The antibody panel:
- Monomer purity (SEC-HPLC): aggregation is the primary quality risk
- Aggregate content (SEC-HPLC): quantified separately from the monomer peak
- Identity and chain integrity (SDS-PAGE, reduced and non-reduced): ~150 kDa intact; ~50 and ~25 kDa on reduction
- Identity (deglycosylated intact mass): the mass check that works on a glycosylated protein
- Binding activity (ELISA against immobilised activin A): pure but inactive is a failed lot
- Selectivity (counter-screen across the ligand family): the property the compound is bought for
- Endotoxin (LAL): mammalian cell culture product
- Concentration (UV A280): reported, not assumed
Handling and storage
- Lyophilized, unopened: 2 to 8 degrees Celsius, 24 months
- Reconstitute gently: diluent down the vial wall, swirl, never vortex or shake
- Reconstituted: 2 to 8 degrees Celsius up to 4 weeks, or single-use aliquots at minus 80 degrees Celsius
- Aliquot before freezing: freeze-thaw cycling is the dominant aggregation driver
- Avoid foaming and unnecessary transfers: the air-liquid interface denatures antibody
Quality standards
- Monomer purity: 98 percent or greater by SEC-HPLC, aggregates reported separately
- Expression system: CHO mammalian cell culture, Protein A purified
- Endotoxin: less than 1.0 EU/mg by LAL
- Form: lyophilized from a histidine and sucrose matrix in single-use vials
- Documentation: batch-matched antibody Certificate of Analysis published at /lab-results
- Fill strengths: 0.1 mg, 1 mg, 5 mg, 10 mg and 100 mg, priced per vial
For laboratory research purposes only. Not for human consumption, therapeutic use, or any in vivo application in humans. Garetosmab is approved in the US only as the medicine Pasatru; the material supplied here is a research reagent, not that medicine.
Research Context for Garetosmab
Muscle Growth and Anabolic Research Context
Muscle growth research peptides study protein synthesis kinetics, satellite cell activation, hyperplasia versus hypertrophy pathways, and the balance of anabolic versus catabolic signaling under controlled conditions. These protocols often involve combination work with growth hormone secretagogues or IGF analogs to probe mechanistic independence.
Garetosmab ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Growth hormone category, with 5 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation on this batch's Certificate of Analysis, published for the batch we're shipping now. Every released batch is listed on the lab results page.
Related Research Guides
Other Compounds in the Growth hormone Category
Research Tools for This Compound
Frequently Asked Questions
What is Garetosmab?
Garetosmab (development code REGN2477, CAS 2097125-54-5) is a fully human IgG4 monoclonal antibody that binds and neutralises activin A. It was generated by Regeneron on the VelocImmune platform, approximately 145.5 kDa, expressed in CHO mammalian cell culture and purified by Protein A affinity chromatography. It is supplied here as a research reference standard only and is not approved as a medicine in any jurisdiction.
Is Garetosmab a peptide?
No. Garetosmab is a monoclonal antibody, not a peptide. It is a fully human IgG4 immunoglobulin of approximately 145.5 kDa, built from two heavy chains and two light chains with interchain disulfide bonds and N-linked glycosylation. Solid-phase peptide synthesis cannot produce a molecule of this size or architecture. This determines how it is tested, stored and handled, and it is why the Certificate of Analysis uses SEC-HPLC and SDS-PAGE rather than the reversed-phase HPLC panel used for peptides.
How much does Garetosmab cost?
Garetosmab is priced per single vial, not per 10-vial kit like the peptide catalogue, and five fill strengths are available: 0.1 mg from $720, 1 mg from $1,255, 5 mg from $3,295, 10 mg from $4,185 and 100 mg from $8,895. The standard quantity discount ladder applies per vial ordered, reaching 42 percent off at the deepest tier. Live pricing in your local currency is shown on this page. Antibody production costs an order of magnitude more per milligram than peptide synthesis, which is why these sit well above the rest of the catalogue.
What exactly does Garetosmab bind?
Garetosmab binds and neutralises activins containing the inhibin beta-A subunit: activin A, activin AB and activin AC. It works as a ligand trap, blocking engagement with the activin type II receptors ActRIIA and ActRIIB and preventing downstream SMAD2 and SMAD3 phosphorylation. It does not bind or functionally inhibit activin B, inhibin A, BMP-2, BMP-6, BMP-9, BMP-10, GDF8 (myostatin) or GDF11.
What is the FOP and ACVR1 research context?
Regeneron scientists identified activin A as the driver of heterotopic ossification in fibrodysplasia ossificans progressiva (FOP). In FOP the mutant ACVR1 receptor misreads activin A as a bone-forming signal. In the Phase 2 study, garetosmab cut new heterotopic ossification lesions by 90% to 94% against placebo, which makes it a standard reference tool in ACVR1 research.
Is garetosmab FDA approved?
Yes, as a medicine. The FDA approved garetosmab on 19 August 2026 as Pasatru, for adults with fibrodysplasia ossificans progressiva, after the Phase 3 OPTIMA trial. Material supplied here is a research reagent, unrelated to any clinical supply chain, and is not for human use.
What did COURAGE show about garetosmab?
In Regeneron's Phase 2 COURAGE obesity trial, garetosmab was added on top of semaglutide and trevogrumab. At 26 weeks, lean mass fell 6.5% on semaglutide alone and 2.0% with both antibodies added, the best body-composition result in the study. It also had the most discontinuations for tolerability.
What testing appears on the Garetosmab Certificate of Analysis?
The antibody release panel: monomer purity and aggregate content by SEC-HPLC; identity and chain integrity by SDS-PAGE reduced and non-reduced; identity by deglycosylated intact mass on LC-ESI-QTOF MS; activin A binding activity by ELISA; a selectivity counter-screen across activin B, inhibin A, BMP-2/6/9/10, GDF8 and GDF11; protein concentration by UV A280; bacterial endotoxins by kinetic chromogenic LAL; plus appearance and pH.
How should Garetosmab be reconstituted and stored?
Store the lyophilized vial at 2 to 8 degrees Celsius; stable for 24 months unopened. Reconstitute by adding diluent slowly down the inner wall of the vial and swirling gently until dissolved. Never vortex and never shake: foaming denatures antibody at the air-liquid interface and drives aggregation. Reconstituted material holds for up to 4 weeks at 2 to 8 degrees Celsius, or aliquot into single-use volumes and store at minus 80 degrees Celsius. Always aliquot before freezing, because repeated freeze-thaw cycling is the dominant driver of aggregate formation.
1 vial
$720